心肌病抗凝治疗中国专家共识

标题: 心肌病抗凝治疗中国专家共识
title: Consensus for anticoagulant therapy for cardiomyopathy in China
版本: 原创版
version: Original
分类: 专家共识
classification: Experts consensus
领域: 治疗
field: Treatment
国家和地区: 中国
Country and region: China
指南使用者: 临床医生
Guide users: clinical physician
证据分级方法: Suitable for application: the clinical benefit is clear and should be given priority (equivalent to class I recommendation); Prefer application: most of them can benefit clinically, with good effect, and can be applied in most cases (equivalent to class IIa recommendation); Uncertain application: the evidence of treatment benefit is insufficient, and the application can be weighed according to the actual clinical situation (equivalent to class IIB recommendation); Not suitable for application: clinical application may not be beneficial or damaged, so it is not recommended (equivalent to class III recommendation).
Evidence grading method: 适合应用:临床获益明确,应予优先应用(相当于Ⅰ类推荐); 倾向于应用:临床大多可获益,效果较好,多数情况下可应用(相当于Ⅱa类推荐); 不确定应用:治疗获益证据不充分,可根据临床实际情况权衡应用(相当于Ⅱb类推荐); 不适合应用:临床应用可能无益或受损,不推荐应用(相当于Ⅲ类推荐)。
制定单位: 中华医学会心血管病学分会精准心血管病学学组
Formulating unit: Section of Precision Cardiovascular Medicine of Chinese Society of Cardiology, Precision Cardiovascular
注册时间: 2021-10-08
Registration time:
注册编号: IPGRP-2021CN320
Registration number:
指南制订的目的: 心肌病因其特殊的结构特征,血栓/栓塞风险显著增高。而相应的,高危血栓风险心肌病患者的抗凝药物使用明显不足。目前国内外有部分针对各类心肌病抗凝方案的治疗建议或推荐,但仍无全面针对心肌病的统一抗凝指南或专家共识。本专家共识对各类心肌病的抗凝适应征及方案进行了系统阐述,并根据现有证据做出推荐,以期促进和规范心肌病患者的抗凝治疗方案制定,指导临床应用。
Purpose of the guideline: Due to the special structural characteristics of cardiomyopathy, the risk of thrombosis / embolism is significantly increased. Accordingly, the use of anticoagulants in patients with high-risk thrombotic cardiomyopathy is significantly insufficient. At present, there are some treatment suggestions or recommendations for anticoagulation schemes for various cardiomyopathy abroad, but there is still no unified anticoagulation guidelines or expert consensus for cardiomyopathy. This expert consensus systematically expounds the anticoagulant indications and schemes of various cardiomyopathy, and makes recommendations according to the existing evidence, to promote and standardize the formulation of anticoagulant treatment schemes for patients with cardiomyopathy and guide clinical application.